Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Michael H. Davidson to Atherosclerosis

This is a "connection" page, showing publications Michael H. Davidson has written about Atherosclerosis.

 
Connection Strength
 
 
 
6.579
 
  1. Pulipati VP, Davidson MH. How I treat statin-associated side effects in an outpatient setting. Future Cardiol. 2021 10; 17(7):1249-1260.
    View in: PubMed
    Score: 0.687
  2. Davidson MH. Triglyceride-rich lipoprotein cholesterol (TRL-C): the ugly stepsister of LDL-C. Eur Heart J. 2018 02 14; 39(7):620-622.
    View in: PubMed
    Score: 0.560
  3. McCullough PA, Ballantyne CM, Sanganalmath SK, Langslet G, Baum SJ, Shah PK, Koren A, Mandel J, Davidson MH. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). Am J Cardiol. 2018 04 15; 121(8):940-948.
    View in: PubMed
    Score: 0.559
  4. Robinson JG, Davidson MH. Can We Cure Atherosclerosis? Rev Cardiovasc Med. 2018; 19(S1):S20-S24.
    View in: PubMed
    Score: 0.556
  5. Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013 Dec 10; 62(23):2178-84.
    View in: PubMed
    Score: 0.412
  6. Mangalmurti SS, Davidson MH. The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk. Curr Atheroscler Rep. 2011 Oct; 13(5):373-80.
    View in: PubMed
    Score: 0.360
  7. Davidson MH. Therapies targeting exogenous cholesterol uptake: new insights and controversies. Curr Atheroscler Rep. 2011 Feb; 13(1):95-100.
    View in: PubMed
    Score: 0.344
  8. Ohsfeldt RL, Gandhi SK, Fox KM, Bullano MF, Davidson M. Medical and cost burden of atherosclerosis among patients treated in routine clinical practice. J Med Econ. 2010; 13(3):500-7.
    View in: PubMed
    Score: 0.319
  9. Davidson MH. Apolipoprotein measurements: is more widespread use clinically indicated? Clin Cardiol. 2009 Sep; 32(9):482-6.
    View in: PubMed
    Score: 0.312
  10. Davidson MH. Pharmacological approaches to modifying HDL: more basic science to understand HDL metabolism is necessary. Editorial to: "NO-1886 up-regulates Niemann-Pick C1 protein (NPC1) expression through liver X receptor alpha signaling pathway in THP-1 macrophage-derived foam cells" by Xin Ma et al. Cardiovasc Drugs Ther. 2009 Jun; 23(3):187-8.
    View in: PubMed
    Score: 0.306
  11. Davidson MH, Gandhi SK, Ohsfeldt RL, Fox KM. Hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring in patients with a diagnosis of atherosclerosis in clinical practice. Am J Med. 2009 Jan; 122(1 Suppl):S51-9.
    View in: PubMed
    Score: 0.298
  12. Davidson MH, Dembowski E. Atherosclerosis surrogate imaging trials come of age: for better or for worse? Curr Cardiol Rep. 2008 Nov; 10(6):521-5.
    View in: PubMed
    Score: 0.294
  13. Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008 Jun 16; 101(12A):41F-50F.
    View in: PubMed
    Score: 0.287
  14. Davidson MH. Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors. Am J Manag Care. 2007 Dec; 13 Suppl 10:S260-9.
    View in: PubMed
    Score: 0.276
  15. Davidson MH. Rosuvastatin in elderly patients. Drugs Aging. 2007; 24(11):933-44.
    View in: PubMed
    Score: 0.259
  16. Rosenson RS, Davidson MH, Hirsh BJ, Kathiresan S, Gaudet D. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014 Dec 16; 64(23):2525-40.
    View in: PubMed
    Score: 0.112
  17. [Official document of the International Society of Atherosclerosis: general recommendations for treatment of dyslipidemia. Executive summary]. Clin Investig Arterioscler. 2014 Jan-Feb; 26(1):33-7.
    View in: PubMed
    Score: 0.104
  18. Maki KC, Dicklin MR, Davidson MH, Mize PD, Kulkarni KR. Indicators of the atherogenic lipoprotein phenotype measured with density gradient ultracentrifugation predict changes in carotid intima-media thickness in men and women. Vasc Health Risk Manag. 2012; 8:31-8.
    View in: PubMed
    Score: 0.092
  19. Toth PP, Ballantyne CM, Davidson MH, Tomassini JE, Ramey DR, Neff D, Tershakovec AM, Hu XH, Tunceli K. Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. J Clin Lipidol. 2012 Mar-Apr; 6(2):180-91.
    View in: PubMed
    Score: 0.091
  20. Davidson MH. Update on CETP inhibition. J Clin Lipidol. 2010 Sep-Oct; 4(5):394-8.
    View in: PubMed
    Score: 0.083
  21. Robinson JG, Davidson M. Is it over for ezetimibe? Expert Rev Cardiovasc Ther. 2008 Jul; 6(6):781-3.
    View in: PubMed
    Score: 0.072
  22. Davidson MH, McKenney JM, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol. 2006 Nov 07; 48(9):1774-81.
    View in: PubMed
    Score: 0.064
  23. Davidson MH, Bays HE, Stein E, Maki KC, Shalwitz RA, Doyle R. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Clin Cardiol. 2006 Jun; 29(6):268-73.
    View in: PubMed
    Score: 0.062
  24. Moriarty PM, Gorby LK, Stroes ES, Kastelein JP, Davidson M, Tsimikas S. Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis. Curr Atheroscler Rep. 2020 07 25; 22(9):48.
    View in: PubMed
    Score: 0.041
  25. Sampson UK, Harrell FE, Fazio S, Nwosu S, Mercaldo N, Mensah GA, Davidson MH, Coll B, Feinstein SB. Carotid adventitial vasa vasorum and intima-media thickness in a primary prevention population. Echocardiography. 2015 Feb; 32(2):264-70.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.